New form of Alzheimer's disease discoveredNovember 04, 2003According to Professor Matti Haltia, a new form of the hereditary disorder Alzheimer's disease, which paralyses the lower extremities of its victims, has been discovered in Finland. This disease has since also been discovered in many other countries. The disorder is caused by a new type of genetic defect, which leads to the accumulation of cotton-wool plaque in the cerebral cortex. These cotton-wool plaques lack the traditional Alzheimer plaques, i.e. an amyloid core. This discovery is altering the understanding of how Alzheimer's disease is formed. Haltia's research was part of the Academy of Finland's Research Programme on Ageing. Genetic research was conducted in co-operation with American professor John Hardy, who was the first to discover the genetic defect that causes Alzheimer's disease in 1991. Professor Haltia and his research group have shown that Alzheimer's disease is even more common among people over 85 years of age than previously thought. Furthermore, the research found that a certain form of the LPL protein protects against cerebral infarction. This represents the first known common hereditary factor related to cerebral infarction. Haltia's group research has also proven that the 'Pohjoinen' epilepsy discovered in the Kainuu region of Finland is a new NCL disease. The genetic defect that causes the disease was identified by the research group headed by Professor Anna-Elina Lehesjoki. Even in Finland, NCL diseases are some of the most common hereditary brain disorders among children. They lead to the accumulation of lipofuscin (ageing pigment) type material in nerve cells and the destruction of nerve cells. In this sense they may serve as models of ageing. Professor Hilkka Soininen was the director of the Ageing Research Programme, which studied mild cognitive impairment (MCI), which is a preliminary stage of Alzheimer's disease. MCI has attracted interest as an intermediary stage between normal ageing and Alzheimer's disease. Approximately 10% of those suffering from MCI develop Alzheimer's disease every year. The project looked at factors, which predict the transformation of MCI into Alzheimer's disease. It also examined the connection of lifestyle and cardiovascular disorder risk factors with MCI and the costs incurred by MCI. The study found that a high cholesterol levels and high blood pressure in middle age is a risk factor for developing Alzheimer's disease in old age, and that high cholesterol levels in middle age is also a risk factor for developing MCI. The research of hereditary degenerative brain disorders helps in identifying the genes, which are also crucial to the normal function of the brain. Identifying defects in these genes allows for the simple and reliable diagnosis of these disorders. Genetic defects and hereditary risk factors also help in understanding the formation of the disorder at the molecular level. This is a prerequisite for the development of effective medications. The Ageing Research Programme was conducted during the period 2000-2002. The programme consisted of 21 research projects from 12 universities and research institutes, and employed nearly 200 researchers. The project fields ranged from medicine to social sciences, pedagogics and architecture. The total programme budget was EUR 3.4 million, EUR 2.4 million of which was funded by the Academy. Other programme funders were the Ministry of Social Affairs and Health, Finnish Work Environment Fund, Social Insurance Institution of Finland (KELA), Ministry of Education, Ministry of the Environment and the Association of Finnish Local and Regional Authorities. The purpose of the research programme was to use research to help society face the challenges that come with ageing. One key goal was to bring different scientific disciplines together to work toward solving the problems associated with ageing. The success of the programme was measured in terms of scientific and social relevance. An international evaluation panel felt that the co-operation of different scientific fields was extremely important. In the group's opinion three years was far too short a time to effectively complete multidisciplinary research projects. The Academy of Finland intends to support and promote ageing research in the future. Next year, the Academy will participate in an extensive European ageing research co-operative funding network, which is being funded by the European Union. Suomen Akatemia (Academy of Finland) |
|||||||||||||||||||||
| Related Alzheimer Disease Current Events and Alzheimer Disease News Articles Delirium in hospitalized adults: Situation critical, no relief available Every year as many as seven million adults in the United States experience delirium during hospitalization. New data demonstrate potential for early detection of Alzheimer's disease Data published in the June issue of the Journal of Alzheimer's Disease demonstrated that minimally-invasive biospectroscopy was able to identify changes in oxidative stress (OS) levels in blood plasma, which may prove to be a useful biomarker in the early detection of Alzheimer's disease. Another McGill/JGH breakthrough opens door to early Alzheimer's diagnosis A new diagnostic technique which may greatly simplify the detection of Alzheimer's disease has been discovered by researchers at McGill University and the affiliated Lady Davis Institute for Medical Research at Montreal's Jewish General Hospital (JGH). Measuring brain atrophy in patients with mild cognitive impairment Scientists at the University of California, San Diego School of Medicine have shown that a fully automated procedure called Volumetric MRI - which measures the "memory centers" of the brain and compares them to expected size - is effective in predicting the progression from mild cognitive impairment (MCI) to Alzheimer's disease. Commonly used medications may produce cognitive impairment in older adults Many drugs commonly prescribed to older adults for a variety of common medical conditions including allergies, hypertension, asthma, and cardiovascular disease appear to negatively affect the aging brain causing immediate but possibly reversible cognitive impairment, including delirium, in older adults. Commonly used ulcer drugs may offer treatment potential in Alzheimer's disease In a new study, published in the May issue of Elsevier's Experimental Neurology, scientists at the University of British Columbia have discovered that drugs commonly used to treat ulcers have significant neuroprotective properties, which appear to be enhanced when used in combination with ibuprofen, a widely used anti-inflammatory drug. New test for mysterious metabolic diseases developed at Stanford/Packard Scientists at Stanford University School of Medicine have devised a much-needed way to monitor and find treatments for a mysterious and devastating group of metabolic diseases that arise from mutations in cells' fuel-burning mechanism. Recalibrating 'fight or flight' A Canadian/U.S. research team has reported a novel approach to stimulating recovery from chronic stress disorders. Details of the therapeutic model, which exploits the natural dynamics of the body's "fight or flight" system, are published January 23 in the open-access journal PLoS Computational Biology Vitamin B does not slow cognitive decline in Alzheimer's A clinical trial led by Paul S. Aisen, M.D., professor of neurosciences at the University of California, San Diego School of Medicine, showed that high-dose vitamin B supplements did not slow the rate of cognitive decline in patients with mild to moderate Alzheimer disease. Protecting patient privacy the new fashioned way Protecting patient privacy has been recognized as the duty of health-care providers for about as long as doctors have seen patients. In 1996 that duty became a legal obligation when Congress passed the Health Insurance Portability and Accountability Act. More Alzheimer Disease Current Events and Alzheimer Disease News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||